How Nutriset, a French company, has helped alleviate hunger and create jobs in some of the world's poorest places
These numbers are staggering, especially because a lifesaving treatment has existed for nearly three decades: 'ready-to-use therapeutic food.'
Nutriset, a French company, was founded by Michel Lescanne. He was one of two scientists who invented this product in 1996. A sticky peanut butter paste branded Plumpy'nut, it's enriched with vitamins and minerals and comes in packets that require no refrigeration or preparation.
Health care professionals were quickly convinced of its promise. What was harder to figure out was how to manufacture as many packets as possible while cutting costs. In 2008, ready-to-use therapeutic food producers like Nutriset charged US$60 for one box of 150 packets – the number needed to treat one severely malnourished child for the 6-8 weeks needed for their recovery.
In a study we published in the Journal of Management Studies in October 2024, we explained how the international agencies, nongovernmental organizations, activists and for-profit companies involved in the product's distribution managed to resolve a public controversy over the use of Nutriset's patent and its for-profit business model.
Contrary to the expectations of activists and many humanitarian NGOs, this for-profit company managed to reduce its prices down to $39 per box of Plumpy'nut packets by 2019 and keep them consistently lower than any nonprofit or for-profit competitors could, all the while enforcing its patent rights.
We interviewed Jan Komrska, a pharmacist then serving as the ready-to-use therapeutic food procurement manager at UNICEF, the United Nations agency for children; Tiddo von Schoen-Angerer, a pediatrician who was leading the access to medicines campaign at Doctors Without Borders, a medical charity; and Thomas Couaillet, a Nutriset executive. We also studied documents issued over the course of a decade to find out why this company's unusual approach to intellectual property protection was so successful.
Nutriset and humanitarian organizations disagreed at the start over how to proceed with the production of ready-to-use therapeutic food.
Doctors Without Borders at first accused Nutriset of behaving like a big drugmaker, shielding itself from competition by aggressively enforcing its patents to charge excessively high prices. The nongovernmental organization demanded that Nutriset allow any manufacturer to make its patented packets, without any compensation for that intellectual property.
By 2012, Nutriset had changed course. It had stopped being almost the sole producer of ready-to-use therapeutic food and instead allowed licensees and franchisee partners, chiefly located in low-income countries, to make the packets without having to pay any royalties. It did, however, make an exception for the United States. It allowed Edesia, a Rhode Island-based nonprofit, to become a Nutriset franchisee.
It also provided these smaller producers with seed funding and technical advice.
Nutriset is still the world's largest ready-to-use therapeutic food producer, we have determined through our research. It's responsible for about 30% to 40% of the world's annual production, down from more than 90% in 2008.
There are some other U.S. manufacturers, such as Tabatchnick Fine Foods, but they aren't Nutriset partners.
At the same time, the company continued to threaten to take legal action against potential rivals located in developed countries that were replicating their recipe without authorization. Usually, cease-and-desist letters were sufficient.
Nutriset implemented this strategy to ward off competition from big multinational corporations that might try to establish their brands in new markets, gaining a foothold before flooding them with imported ultraprocessed food. A big risk, had that occurred, would have been less breastfeeding for newborns and the disruption of local diets.
Nutriset's strategy of opening access to its patent selectively has enabled UNICEF to double the share of packets it buys from producers located in the Global South.
UNICEF, the world's biggest buyer of ready-to-use therapeutic food, bought less than one-third of its supplies from those nations in 2011. That share climbed to two-thirds in 2022.
Nutriset's reliance on local franchisees has helped create over 1,000 jobs in hunger-stricken regions while strengthening the supply chain and reducing the carbon emissions of transportation, according to UNICEF.
Nutriset's creative patent strategy also helped its partner producers in low-income countries, which include nonprofit and for-profit ventures, compete with large corporations in developed countries by the time its patent expired in 2018.
In this instance, a for-profit company not only managed to keep its prices lower than its competitors, including nonprofits, but used its patent to support economic development in developing countries by shielding startup producers from international competition.
As a result of these successes, we found that nongovernmental organizations eventually stopped criticizing the French company and recognized that high prices were actually not due to Nutriset's patent policy but rather to global prices of the packets' ingredients.
In recognition of its contributions and innovation, Nutriset won the U.S. Patent and Trademark Office's Patents for Humanity Award in 2015.
One of the biggest advantages of ready-to-use therapeutic food is that parents or other caregivers can give it to their kids at home or on the go. That's more convenient and cheaper than the alternative: several months of hospitalization where children receive a nutrient-dense liquid called 'therapeutic milk.'
The at-home treatment works most of the time. More than 80% of the children who get three daily food packets recover within two months.
Severe acute malnutrition deaths remain high because historically only 25% to 50% of children suffering from it get treated with ready-to-use therapeutic food, due to insufficient funding. The treatment programs are run by governments, UNICEF and other international agencies, and NGOs such as Doctors Without Borders.
The U.S. government spent about $200 million in 2024 through the U.S. Agency for International Development on ready-to-use therapeutic food, enough packets to treat 3.9 million children. That's nearly as much as UNICEF, which treats about 5 million children annually.
It's unclear whether the Trump administration, which is trying to dismantle USAID, will discontinue its funding of ready-to-use therapeutic food that the U.S. government has purchased exclusively from U.S. manufacturers with U.S.-sourced ingredients.
At a time when the flow of development aid from several wealthy countries is declining, the precedent Nutriset set suggests that humanitarian organizations, by teaming up with international agencies, governments and for-profit companies, can help drive down the costs of saving lives threatened by hunger while increasing the nutritional autonomy of the Global South.
But the funding for ready-to-use therapeutic food and its distribution has to come from somewhere, whether it is from governments, foundations or other donors.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Nicolas Dahan, Seton Hall University and Bernard Leca, ESSEC
Read more:
As Trump tries to slash US foreign aid, here are 3 common myths many Americans mistakenly believe about it
How nonprofits abroad can fill gaps when the US government cuts off foreign aid
3 billion people cannot afford a healthy diet
The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
39 minutes ago
- CNN
HHS: How we're fixing the organ transplant system that betrayed America
EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.
CNN
39 minutes ago
- CNN
HHS: How we're fixing the organ transplant system that betrayed America
EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.
CNN
an hour ago
- CNN
HHS: How we're fixing the organ transplant system that betrayed America
EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.
